Merck agent reduces niacin flushing
Executive Summary
Data on Merck's MK-0524, an investigational DP1-receptor antagonist, shows a reduction in flushing in dyslipidemia patients on extended-release niacin. In data presented Nov. 16 at the American Heart Association's Scientific Sessions in Chicago, 37% of patients taking MK-0524 plus niacin reported flushing compared to 61% of patients treated with niacin alone. Merck is in clinical trials for MK-0524a, a fixed-dose combination of niacin and MK-0524 (1"The Pink Sheet" Oct. 2, 2006, In Brief)...
You may also be interested in...
Merck delays Zocor/niacin combo
Merck will not file its fixed-dose combo drug MK-0524B, combining Zocor (simvastatin) and MK-0524A (extended-release niacin and a flushing inhibitor), in 2007 as planned due to formulation problems, the company announces Sept. 29. The company will continue its late-stage clinical program to support the regulatory filing for the LDL-lowering/HDL-raising triple combination, but it did not announce a new timeline for NDA submission. The firm still expects to file MK-0524A in 2007. Merck has continuously said that neither product will affect Vytorin (simvastatin/ezetimibe), which it co-markets with Schering-Plough (1"The Pink Sheet" Jan. 16, 2006, p. 12)...
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: